Kupando Announces First Patient Dosed in Phase 1 Clinical Study of Lead Candidate KUP101 in Advanced Solid Tumours
Milestone marks Kupando's evolution from a research-focused organisation to a clinical-stage biopharmaceutical company
Phase 1 trial evaluates KUP101, a diff...



















